The Latest Breaking News from Eli Lilly

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

The stock market is at highs with Apple's AI push, the Fed rate "dot-plot" and the Tesla shareholder meeting headlining key events and news.

With weight-loss drugs gaining traction, which biopharma stock wins?

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Google-parent Alphabet announced that its new chief financial officer will be Anat Ashkenazi, currently an executive at pharmaceutical company Eli Lilly.

As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.